Q-omics provides the consensus-scored SYT10 profile across patient tissues and cancer cell-line models. SYT10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SYT10 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SYT10 RNA expression shows 13,547 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where SYT10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT10 survival associations across molecular data types. SYT10 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT10 RNA expression–survival associations across cancer types. High SYT10 expression shows unfavorable associations in MESO and UCEC, but favorable associations in SCLC, LGG, PAAD and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SYT10 RNA expression.
This table summarizes SYT10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SYT10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT10 shows lower tumor expression in COAD, KIRC, LIHC, READ and STAD and higher tumor expression in KICH. The COAD box plot shows higher SYT10 RNA expression in normal versus tumor tissue (log2 FC = −0.336, t-test p < 0.001).
This table shows molecular features associated with SYT10 in patient tissues and cancer cell lines. In patient samples, SYT10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
